DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,821,575 | +0.8% | 19,434 | -2.4% | 0.85% | +2.8% |
| Q2 2023 | $4,781,280 | -3.6% | 19,922 | +1.3% | 0.83% | -7.0% |
| Q1 2023 | $4,957,375 | -6.7% | 19,669 | -1.7% | 0.89% | -7.0% |
| Q4 2022 | $5,311,320 | +1.1% | 20,011 | -1.7% | 0.96% | -8.7% |
| Q3 2022 | $5,256,000 | +9.8% | 20,348 | +7.8% | 1.05% | +14.7% |
| Q2 2022 | $4,785,000 | -14.4% | 18,873 | -0.9% | 0.91% | +1.9% |
| Q1 2022 | $5,589,000 | -14.8% | 19,052 | -4.5% | 0.90% | -7.4% |
| Q4 2021 | $6,563,000 | -26.1% | 19,948 | -31.6% | 0.97% | -28.8% |
| Q3 2021 | $8,880,000 | +8.2% | 29,167 | -4.6% | 1.36% | +12.6% |
| Q2 2021 | $8,206,000 | +17.6% | 30,579 | -1.4% | 1.21% | +10.5% |
| Q1 2021 | $6,980,000 | +2.0% | 31,013 | +0.7% | 1.09% | -3.2% |
| Q4 2020 | $6,843,000 | -12.5% | 30,804 | -15.2% | 1.13% | -21.4% |
| Q3 2020 | $7,820,000 | +19.5% | 36,315 | -1.9% | 1.44% | +16.6% |
| Q2 2020 | $6,544,000 | +25.6% | 37,007 | -1.7% | 1.23% | +7.0% |
| Q1 2020 | $5,209,000 | -11.2% | 37,635 | -1.5% | 1.15% | +14.1% |
| Q4 2019 | $5,864,000 | -74.9% | 38,205 | -76.4% | 1.01% | -60.3% |
| Q3 2019 | $23,337,000 | +0.6% | 161,579 | -0.5% | 2.54% | +5.4% |
| Q2 2019 | $23,202,000 | -13.5% | 162,341 | -20.1% | 2.41% | -14.8% |
| Q1 2019 | $26,812,000 | +24.7% | 203,094 | -2.6% | 2.83% | +10.8% |
| Q4 2018 | $21,507,000 | -8.5% | 208,558 | -3.6% | 2.55% | +8.8% |
| Q3 2018 | $23,502,000 | +16.4% | 216,290 | +5.7% | 2.34% | +11.1% |
| Q2 2018 | $20,190,000 | -4.3% | 204,598 | -5.0% | 2.11% | -3.6% |
| Q1 2018 | $21,097,000 | +4.9% | 215,471 | -0.6% | 2.19% | +10.3% |
| Q4 2017 | $20,115,000 | +4.9% | 216,711 | -3.1% | 1.98% | +4.6% |
| Q3 2017 | $19,175,000 | -0.2% | 223,539 | -1.8% | 1.90% | -6.2% |
| Q2 2017 | $19,216,000 | -12.0% | 227,709 | -10.8% | 2.02% | -11.5% |
| Q1 2017 | $21,840,000 | +10.5% | 255,350 | +0.6% | 2.29% | +8.7% |
| Q4 2016 | $19,762,000 | -1.6% | 253,880 | -0.9% | 2.10% | -4.5% |
| Q3 2016 | $20,087,000 | -57.9% | 256,241 | -45.8% | 2.20% | -39.2% |
| Q2 2016 | $47,761,000 | -37.4% | 472,880 | -41.2% | 3.62% | -8.9% |
| Q1 2016 | $76,257,000 | +48.8% | 803,894 | +45.7% | 3.98% | +4.6% |
| Q4 2015 | $51,255,000 | +6.5% | 551,844 | -2.3% | 3.80% | +7.6% |
| Q3 2015 | $48,124,000 | -7.7% | 564,774 | -7.3% | 3.54% | +4.4% |
| Q2 2015 | $52,126,000 | +45.9% | 609,024 | +44.7% | 3.39% | -19.0% |
| Q1 2015 | $35,732,000 | -1.4% | 420,873 | -0.5% | 4.18% | +37.3% |
| Q4 2014 | $36,255,000 | +17.2% | 422,998 | +3.9% | 3.04% | +8.4% |
| Q3 2014 | $30,924,000 | +19.4% | 406,998 | +23.7% | 2.81% | +7.0% |
| Q2 2014 | $25,910,000 | +177.4% | 329,098 | +164.3% | 2.62% | +65.8% |
| Q1 2014 | $9,341,000 | +67.4% | 124,540 | +72.3% | 1.58% | +36.7% |
| Q4 2013 | $5,579,000 | +8.4% | 72,270 | -2.7% | 1.16% | +4.3% |
| Q3 2013 | $5,149,000 | +9.6% | 74,275 | +0.1% | 1.11% | +8.5% |
| Q2 2013 | $4,699,000 | – | 74,230 | – | 1.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |